Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
XM22 vs pegfilgrastim in breast cancer patients receiving chemotherapy
2009-015999-10Phase 3Completed
- Sponsor
- BioGeneriX AG
- Start
- Feb 2010
- Modality
- Cytokines & Interferons → Recombinant Proteins and Enzymes, Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of lipegfilgrastim in breast cancer (2 arms), sponsored by BioGeneriX AG. Primary endpoint: Duration of severe neutropenia in cycle 1. Started Feb 2010; status: completed.
02
Drugs
lipegfilgrastim
03
Conditions
breast cancer
Beyond the preview
Go deeper on 2009-015999-10.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2009-015999-10.